The first participants have been dosed in an early Phase 1 clinical study that’s testing NRG5051, a first-in-class treatment candidate for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, in healthy volunteers. Developed by NRG Therapeutics, the experimental therapy is designed to restore the health of mitochondria, known…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to VectorY Therapeutics’ lead investigational therapy, VTx-002, to treat amyotrophic lateral sclerosis (ALS). The antibody gene therapy is designed to clear toxic TDP-43 protein clumps, a hallmark of ALS. Fast-track status is designed to expedite the development…
The ALS Association is urging members of Congress to take action to address issues with instability in leadership at the National Institutes of Health (NIH). At issue is the Trump administration’s decision not to renew the contract of Walter J. Koroshetz, MD, the director of the National Institute of…
Aperture Therapeutics said it is advancing its RNA-targeting therapy APRTX-003 as a potential treatment for amyotrophic lateral sclerosis (ALS). The therapy, currently in preclinical development, is designed to reduce the production of matrix metalloproteinase-9 (MMP-9) by targeting its template RNA molecule. When overactive, this enzyme may lead to…
Tanabe Pharma plans to establish a new U.S.-based company to hold the global rights to Radicava and Radicava ORS, two edaravone formulations approved to treat amyotrophic lateral sclerosis (ALS), which Shionogi plans to acquire and operate as a wholly owned subsidiary. “We are pleased to welcome Radicava…
Both people living with amyotrophic lateral sclerosis (ALS) and their caregivers benefit most from flexible, personalized psychological support that combines emotional care and open dialogue, a new study from Germany suggests. Critical, the researchers say, is to create a framework that can be easily adjusted to a patient and…
QRL-101, an experimental oral small molecule being developed by Quralis for amyotrophic lateral sclerosis (ALS), was found in an early clinical trial to engage its intended biological target and reduce nerve cell overactivity in people with ALS. These results come from a proof-of-mechanism Phase 1 clinical study…
Health Canada has cleared the way for people with amyotrophic lateral sclerosis (ALS) living in Canada to join an ongoing clinical trial evaluating Coya Therapeutics’ therapy candidate COYA 302. The Canadian regulatory agency issued a “no objection” letter that will allow the developer to start enrolling adults in…
Some people with amyotrophic lateral sclerosis (ALS) who received Qalsody (tofersen) in the VALOR trial experienced improvements in physical function, lung function, and muscle strength over about three years of treatment, a new analysis found. Gains were observed more often among those who started treatment in the main…
Throughout 2025, ALS News Today delivered readers timely reporting on research breakthroughs, patient advocacy, potential treatments, and diagnostic advances for amyotrophic lateral sclerosis (ALS). Below are the top 10 most-read news stories for a recap of the year, each accompanied by a summary. As we enter 2026, we…
